相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
T. Heise et al.
DIABETES OBESITY & METABOLISM (2013)
Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter Inhibitor, as Add-On to Meiformin in Subjects With Type 2 Diabetes
Julio Rosenstock et al.
DIABETES CARE (2012)
Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats
L. Thomas et al.
DIABETES OBESITY & METABOLISM (2012)
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
R. Grempler et al.
DIABETES OBESITY & METABOLISM (2012)
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
Ele Ferrannini et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes
Edward C. Chao
CORE EVIDENCE (2012)
Learning From Glycosuria
Ele Ferrannini
DIABETES (2011)
Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans
James F. List et al.
KIDNEY INTERNATIONAL (2011)
SGLT2 inhibition - a novel strategy for diabetes treatment
Edward C. Chao et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999-2004
Allison Hedley Dodd et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Prevention and early detection of vascular complications of diabetes
Sally M. Marshall et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Mechanism by which metformin reduces glucose production in type 2 diabetes
RS Hundal et al.
DIABETES (2000)
分享论文
